Immunetrics’ disease models span across acute inflammation, chronic, autoimmune conditions, and immuno-oncology.

These models can be customized to meet specific needs and are constantly evolving to support new research outcomes.

 

Disease Models

 

Key Outputs

 

Supported Therapeutics

Rheumatoid Arthritis

 

 

Swollen/tender joint counts (SJC/TJC)

ACR20/50/70/90

DAS28(3)-CRP/ESR

Low disease activity

Remission

Serum cytokines and biomarkers

Serum cell counts

MTX

5-ASA

Corticosteroids

JAK inhibitors

Anti-TNFs

Anti-IL6s

Anti-IL17s

Anti-T and B cell therapies

Anti-Survival therapies

Anti-Migration therapies

Psoriatic Arthritis / Psoriasis

Swollen/tender joint counts

ACR20/50/70

DAS28(3)-CRP/ESR

PASI 50/75/90/100

Serum cytokines and biomarkers

Serum cell counts

MTX

5-ASA

Corticosteroids

JAK inhibitors

Anti-TNFs

Anti-IL6s

Anti-IL17s

Anti-IL12/23

Anti-T and B cell therapies

Anti-Survival therapies

Anti-Migration therapies

Ulcerative Colitis

Mayo score

Response/Remission

Mucosal healing

Serum cytokines and biomarkers

MTX

5-ASA

Corticosteroids

Anti-TNFs

JAK inhibitors

S1P receptor antagonist
Acute Myeloid Leukemia (AML)

Best Overall Response (BOR) based on bone marrow and blood blast counts:

  • Complete Response (CR)
  • Partial Response (PR)
  • Stable Disease (SD)
  • Partial Disease (PD)

Response vs Non-response

Minimal Residual Disease (MRD = < 0.1% Blasts)

Death

Duration of Response (DoR)

Relapse

Disease-specific Biomarkers: 

  • Percent Blasts (Bone marrow and blood)

Hypomethylating Agents (i.e. azacytidine)

Chemotherapies (cytarabine)

BCL-2 inhibitor (venetoclax)

Monoclonal antibodies (e.g. anti-CD47) 
Multiple Myeloma (MM)

Best Overall Response (BOR) based on M-protein changes:

  • Complete Response (CR)
  • Very Good Partial Response (VGPR)
  • Partial Response (PR)
  • Stable Disease (SD)
  • Partial Disease (PD)

Overall Response Rate (ORR)

Time To Response (TTR)

Duration of Response (DoR) 

Disease-specific Biomarkers: 

  • Soluble B-Cell Maturation Antigen (sBCMA) 
  • M-Protein 
  • soluble Free Light Chain (sFLC) 

Immunomodulatory Drugs (IMiDs)

Antibody-Drug Conjugates (ADCs)

Immune Cell Engagers (NK and T cell Engagers) 

Monoclonal Antibodies (e.g. Daratumumab)

Chimeric Antigen Receptor T cell Therapies (CAR T therapies)

Steroids (i.e. Dexamethasone) 
Melanoma*

Tumor Size

Best Overall Response (BOR)

  
Client Proprietary
Non-small cell lung cancer (NSCLC)*

Percent change in Tumor Diameter

Best Overall Response (BOR)

Progressive Disease (PD)

Stable Disease (SD)

Responders (RR)

Monoclonal Antibodies

  • anti-PD-1 (Nivolumab and Pembrolizumab)
  • anti-CTLA-4 (Ipilimumab)

Chemotherapies

  • alkylating agents (Carboplatin)
  • cytoskeletal drugs (Paclitaxel)
Diffuse large B cell lymphoma
(DLBCL)*

Complete Responder (CR)

Partial Responder (PR)

Tumor Cell Number

Chimeric Antigen Receptor T cell Therapies (CAR T therapies)

  • ricAxiabtagene ciloleucel (axi-cel)
  • Tisgenlecleucel (CTL019)

R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) 

Immunomodulatory Drugs (IMiDs)

  • Lenalidomide

Sepsis

Multi-Organ Dysfunction

 

Mean arterial pressure (MAP)

Central venous pressure (CVP)

Blood oxygen saturation (O2sat)

Breathing frequency

Tidal volume

Blood gases (PaO2, PaCO2)

Creatinine

Urinary output (UOP)

Coagulation proteins

Fluid therapy

Vasopressors

Ventilators

Diuretics

Dialysis

Antibiotics

Trauma

Cytokines

Immune cells

Coagulation proteins

Blood loss

Mean arterial pressure (MAP)

Blood oxygen saturation (O2sat)

Fluid therapies

Blood products

Ventilators

* Indicates models developed internally OR for a specific purpose. These models are currently limited in functionality compared to our platform models.